How I Manage Patients with Chronic Myeloid Leukemia (CML): Perspectives from Clinical Practice

IF 3.9 Q2 ONCOLOGY

Blood and Lymphatic Cancer-Targets and Therapy Pub Date : 2022-03-01 DOI:10.2147/BLCTT.S219160

G. S. Guru Murthy

引用次数: 0

Abstract

Abstract The management of chronic myeloid leukemia (CML) has remarkably changed in the last 20 years with the availability of tyrosine kinase inhibitors (TKI). Most patients with chronic phase CML now have a life expectancy like that of age matched controls. Understanding the practical aspects of choosing the appropriate TKI, monitoring response and side-effects are key to long term success. Currently, treatment cessation is also an option in patients achieving sustained deep molecular response. Novel agents are needed in patients with lack of response to TKI and in those with advanced disease.

查看原文本刊更多论文

我如何管理慢性髓性白血病(CML)患者:从临床实践的角度

随着酪氨酸激酶抑制剂(TKI)的出现，慢性髓性白血病(CML)的治疗在过去20年中发生了显著变化。大多数慢性粒细胞白血病患者现在的预期寿命与年龄匹配的对照组相似。了解选择合适TKI的实际方面，监测反应和副作用是长期成功的关键。目前，停止治疗也是获得持续深层分子反应的患者的一种选择。对TKI缺乏反应的患者和晚期疾病患者需要新型药物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Blood and Lymphatic Cancer-Targets and Therapy ONCOLOGY-

自引率

7.10%

发文量

审稿时长

16 weeks

期刊介绍： Blood and Lymphatic Cancer: Targets and Therapy is an international, peer reviewed, open access journal focusing on blood and lymphatic cancer research, identification of therapeutic targets, and the optimal use of preventative and integrated treatment interventions to achieve improved outcomes, enhanced survival, and quality of life for the cancer patient. Specific topics covered in the journal include: Epidemiology, detection and screening Cellular research and biomarkers Identification of biotargets and agents with novel mechanisms of action Optimal clinical use of existing anticancer agents, including combination therapies Radiation, surgery, bone marrow transplantation Palliative care Patient adherence, quality of life, satisfaction Health economic evaluations.

文献相关原料

公司名称	产品信息	采购帮参考价格